|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.55 HKD | +2.67% |
|
+0.97% | -25.56% |
| Apr. 30 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
| Apr. 29 | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
Keymed Biosciences Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CNY 100.06 million compared to CNY 110.27 million a year ago. Net loss was CNY 308.12 million compared to CNY 3,887.31 million a year ago.
Basic loss per share from continuing operations was CNY 1.18 compared to CNY 24.17 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -25.56% | 1.27B | |
| +10.44% | 106B | |
| +0.82% | 104B | |
| +6.72% | 23.25B | |
| -13.89% | 22.5B | |
| -6.64% | 18.7B | |
| -37.26% | 17.95B | |
| -10.98% | 16.99B | |
| +8.67% | 14.26B | |
| +41.08% | 12.76B |
KEYMED BIOSCIENCES INC. 